What is healthcare market research?

What healthcare market research is

Healthcare market research is the systematic gathering and interpretation of insight from the people who shape healthcare decisions. In practice that means talking to, or measuring the behaviour of, physicians, nurses, pharmacists, payers, hospital administrators, procurement and value analysis teams, patients, caregivers and former industry executives. The purpose is always commercial in the broadest sense: to decide what to build, how to position it, what to charge, how to win coverage and where to launch first.

What separates it from general business research is the subject matter. The questions are simultaneously clinical and commercial — a prescribing decision is a medical judgement constrained by formulary rules, a device purchase is a surgeon's preference constrained by a capital budget. Research that treats either half as background noise produces findings that read well and predict nothing.

Who uses it, and what for

Pharmaceutical and biotech companies use it across the asset lifecycle: shaping a target product profile, testing endpoints and comparators before pivotal trials, sizing opportunity, pressure-testing launch messages and tracking performance afterwards. Medical device, diagnostics and digital health firms use it to understand clinician preference, workflow fit, procurement routes and reimbursement. Consultancies and investors use it for commercial due diligence, where the question is usually whether a management team's assumptions survive contact with practising clinicians.

Health systems and hospital groups commission it too, often to understand referral patterns, service line economics or technology adoption among their own clinicians. The common thread is that each buyer is about to commit money or credibility to a decision, and the cost of being wrong is far larger than the cost of asking first.

Primary and secondary research

Secondary research assembles evidence that already exists: peer-reviewed literature, clinical trial registries, treatment guidelines, epidemiology, prescription and claims data, tender awards, formulary listings and company disclosures. It is fast, comparatively cheap, and the right place to start, because it tells you what is already known and therefore what you do not need to pay respondents to tell you.

Primary research generates new evidence by going directly to stakeholders. It is the only way to answer questions about intent, trade-offs and unmet need — the things nobody has written down yet. A well-run programme uses secondary research to frame the question and set the hypotheses, then spends the primary budget only on what secondary sources genuinely cannot answer.

The main methods

Method choice follows from how well you can already frame the question. If you cannot yet write a sensible multiple-choice answer, you need qualitative work. If you can, and you need to know how many people would pick each option, you need quantitative work. Most of the healthcare toolkit is a variation on one of these:

• Expert calls — a single compliance-screened hour with someone who has made the decision you are facing, usually scheduled within days.
• In-depth interviews — longer, guided conversations run against a discussion guide, recorded and analysed as a set.
• Focus groups and multi-expert panels — several practitioners in one session, used where disagreement between peers is itself the finding.
• Advisory boards — a standing group of senior clinicians or payers convened on a recurring cadence to counsel on strategy.
• Quantitative surveys — structured questionnaires across a specialist sample, sized so results can be cut by specialty, setting and geography.
• Choice experiments — conjoint, MaxDiff, Van Westendorp and Gabor-Granger designs that isolate what actually drives preference and price tolerance.
• Observational work — ethnography, in-clinic immersion, simulated use and video capture, used when what people do diverges from what they report.

How a study actually runs

A study starts with a brief that names the decision, the date it has to be made and the audience that can inform it. From there the research team writes a screener that defines who qualifies, a discussion guide or questionnaire, and a sample plan. All three go through client review and, in many organisations, a compliance and medical-legal review before fieldwork can open.

Recruitment then runs in parallel with fieldwork: respondents are sourced, their credentials verified, conflicts screened and consent recorded, and sessions scheduled. Analysis begins while fieldwork is still live, because early interviews routinely expose a question that was framed wrongly and is still cheap to fix. The programme closes with a readout that states what was found, how confident you should be in it, and what to do next.

Why healthcare research is different

Three constraints make it its own discipline. First, the universe is small: there may be only a few hundred relevant specialists in a country, so a sample of thirty is a meaningful share of the population rather than a rounding error. Second, the respondents are expensive to reach and difficult to schedule, which puts a premium on getting the instrument right the first time. Third, the entire activity is regulated.

That regulation is not administrative overhead — it changes the method. Research must stay non-promotional, avoid off-label probing, report suspected adverse events to pharmacovigilance, pay honoraria benchmarked to fair market value, screen participants for conflicts and confidentiality obligations, and handle personal data under the applicable privacy regime. A firm that treats compliance as paperwork will eventually produce a study you cannot use.

What good research produces

The visible output is usually a report, a set of charts and a quote library, plus transcripts or data tables for the team that wants to go deeper. The useful output is narrower: a clear answer to the question in the brief, an honest statement of where the evidence is thin, and a recommendation someone can take into a decision meeting.

Judge a deliverable by whether it would change anyone's behaviour. A report that describes the market without taking a position has described the problem back to the people who already live in it. Ask prospective partners for a redacted example before you commission, and read the last two pages first.

Where it goes wrong

The most common failure is sequencing: commissioning a large quantitative survey before any exploratory work, which measures the wrong variables very precisely. The second is sample convenience — filling a quota with whoever answers fastest, which quietly over-represents the clinicians least busy with patients. The third is leading design, where the questionnaire tests whether respondents will agree with the strategy rather than whether the strategy is right.

Two more are specific to healthcare. Treating one country's payer structure as a template for another produces confident nonsense, because coverage and pricing mechanics differ fundamentally between systems. And relying on stated intent alone overstates uptake; pairing stated preference with observed behaviour or a choice experiment gives a far more defensible read.